Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2014Website:
http://www.atarabio.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:54:29 GMTDividend
Analysts recommendations
Institutional Ownership
ATRA Latest News
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming milestones for 2024. “Building on the recent BLA acceptance with Priority Review for tab-cel, we are making signifi.
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT. A live web.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.” The award was presented to Pierre Fabre Laborato.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie.
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.
What type of business is Atara Biotherapeutics?
Atara Biotherapeutics, Inc. is a biotechnology company that is developing new methods of treating patients with cancer, autoimmune, and viral diseases. The company specializes in allogeneic T-cell immunotherapy. It was founded in 2012 and is headquartered in San Francisco, California. The company's priority programs/strategies are: - Tab-cel: an advanced T-cell immunotherapy in Phase 3 clinical development, designed for patients with Epstein-Barr virus. - ATA188: T-cell immunotherapy targeting EBV antigens, considered important for potential treatment of multiple sclerosis. - ATA2271/ATA3271: immunotherapy for patients with hematologic malignancies, solid tumors, and viral diseases. - ATA3219: immunotherapy aimed at treating patients with B-cell lymphomas.
What sector is Atara Biotherapeutics in?
Atara Biotherapeutics is in the Healthcare sector
What industry is Atara Biotherapeutics in?
Atara Biotherapeutics is in the Biotechnology industry
What country is Atara Biotherapeutics from?
Atara Biotherapeutics is headquartered in United States
When did Atara Biotherapeutics go public?
Atara Biotherapeutics initial public offering (IPO) was on 16 October 2014
What is Atara Biotherapeutics website?
https://www.atarabio.com
Is Atara Biotherapeutics in the S&P 500?
No, Atara Biotherapeutics is not included in the S&P 500 index
Is Atara Biotherapeutics in the NASDAQ 100?
No, Atara Biotherapeutics is not included in the NASDAQ 100 index
Is Atara Biotherapeutics in the Dow Jones?
No, Atara Biotherapeutics is not included in the Dow Jones index
When was Atara Biotherapeutics the previous earnings report?
No data
When does Atara Biotherapeutics earnings report?
The next expected earnings date for Atara Biotherapeutics is 28 March 2025